SCHEMBL3017993

SCHEMBL3017993

COc1cccc(Cc2csc(N3CCC(S(=O)(=O)c4ccc(OC(F)(F)F)cc4)CC3)n2)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.41
HSD17B10 Q99714 3/20 0.41
USP2 O75604 1/20 0.41
RECQL P46063 1/20 0.41
ALDH1A1 P00352 3/20 0.39
LMNA P02545 3/20 0.39
HPGD P15428 1/20 0.39
PTPRB P23467 1/20 0.38
CHRM5 P08912 1/20 0.38
PRKAA2 P54646 1/20 0.38
EPHX2 P34913 1/20 0.37
GPR6 P46095 1/20 0.36
TP53 P04637 1/20 0.36
TSHR P16473 1/20 0.36
MAPK1 P28482 1/20 0.36
GRIN2B Q13224 1/20 0.36
MCHR1 Q99705 1/20 0.36
SCN9A Q15858 2/20 0.36
PKM P14618 1/20 0.36
MEN1 O00255 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3013530 0.93 RAB9A (0.36) MAPTHSD17B10USP2RECQLTP53
SCHEMBL3019380 0.91 LIPE (0.38) EPHX2SCN9ARAB9A
SCHEMBL3006609 0.91 AVPR1B (0.40) MAPTLMNAEPHX2TP53SMN1; SMN2
SCHEMBL3014347 0.90 HDAC3 (0.35) EPHX2SCN9AMEN1KMT2ARAB9A
SCHEMBL3014608 0.90 MAPT (0.51) MAPTHSD17B10USP2RECQLALDH1A1
SCHEMBL3012372 0.89 MAPT (0.42) MAPTHSD17B10USP2RECQLALDH1A1
SCHEMBL3018194 0.89 HTR2A (0.39) SCN9AMEN1KMT2A
SCHEMBL3013307 0.89 KDM4E (0.40) ALDH1A1LMNAEPHX2MCHR1MEN1
SCHEMBL3006084 0.88 PTPRB (0.41) MAPTHSD17B10USP2RECQLALDH1A1
SCHEMBL3014556 0.88 MAPT (0.42) MAPTHSD17B10USP2RECQLALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885HSD17B10 2553/4885USP2 1831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.